Drugs / VH4770359
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07525544 | May 2026 → May 2027 expected | HIV infectious disease | ViiV Healthcare | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VH4770359 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07525544 ↗ |
| Known as | GSK4770359 | “VH4770359 (also known as GSK4770359) is an antiretroviral compound.” NCT07525544 ↗ |
| Route | Oral | “Participants will receive the assigned dose formulation of VH4770359 orally.” NCT07525544 ↗ |